Li, Pengxiang
Email Address
ORCID
Disciplines
relationships.isProjectOf
relationships.isOrgUnitOf
Position
Introduction
Research Interests
Collection
3 results
Search Results
Now showing 1 - 3 of 3
Publication Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents(2018-01-19) Doshi, Jalpa A; Li, Pengxiang; Pettit, Amy R; Armstrong, Katrina A.High out-of-pocket (OOP) costs may limit access to novel oral cancer medications. In a retrospective study, nearly one third of patients whose OOP costs were $100 to $500 and nearly half of patients whose OOP costs were more than $2,000 failed to pick up their new prescription for an oral cancer medication, compared to 10% of patients who were required to pay less than $10 at the time of purchase. Delays in picking up prescriptions were also more frequent among patients facing higher OOP costs.Publication Impact of Medicare Advantage Prescription Drug Plan Star Ratings on Enrollment Before and After Implementation of Quality-Related Bonus Payments in 2012(2016-06-10) Li, Pengxiang; Doshi, Jalpa AThe five-star quality rating of Medicare Advantage Prescription Drug Plans had no direct impact on same-year enrollment. But after the introduction of a bonus payment for highly-rated plans, which had to be invested in additional benefits and /or reducing premiums, subsequent year enrollment in these plans increased.Publication High Cost Sharing and Specialty Drug Initiation Under Medicare Part D: A Case Study in Patients With Newly Diagnosed Chronic Myeloid Leukemia(2016-04-01) Doshi, Jalpa A; Li, Pengxiang; Huo, Hairong; Pettit, Amy R; Kumar, Rishab; Weiss, Brendan M; Huntington, Scott FMedicare Part D beneficiaries with higher out-of-pocket costs are more likely to delay starting or not start a recommended specialty drug when newly diagnosed with leukemia. Policy changes are needed to ensure optimal access to specialty medications under Medicare Part D.